RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: PRESIDE Trial Meets Primary End Point With Continuous Enzalutamide After Progression of mCRPC – Cancer Network